U.S. markets open in 5 hours 29 minutes

Akouos, Inc. (AKUS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.71+1.08 (+4.21%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close25.63
Open25.78
Bid0.00 x 800
Ask0.00 x 1100
Day's Range25.04 - 28.02
52 Week Range19.00 - 30.67
Volume328,699
Avg. Volume261,798
Market Cap918.039M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Akouos to Present at Cantor Global Virtual Healthcare Conference

      BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will participate in a fireside chat at the Cantor Global Virtual Healthcare Conference on Tuesday, September 15 at 8:00 a.m. ET. A live webcast of the fireside chat will be accessible through the investors section of the company’s website at www.akouos.com. To access the webcast, please go on to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Akouos’s website for 14 days following the conference.About AkouosAkouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.Contacts Media: Katie Engleman, 1AB katie@1abmedia.comInvestors: Courtney Turiano, Stern Investor Relations Courtney.Turiano@sternir.com

    • GlobeNewswire

      Akouos Reports Second Quarter 2020 Financial Results and Provides Business Highlights

      \- Upsized IPO in June 2020 raised $244.4 million in gross proceeds -\- Company plans to advance lead product candidate, AK-OTOF, for the treatment of hearing loss due to mutations in the OTOF gene, to IND submission in 2021 and advance development programs spanning multiple inner ear disorders -BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business highlights.“Our upsized initial public offering, which we completed in June, leaves us in a strong position to continue to advance our lead product candidate, AK-OTOF, for the treatment of hearing loss due to mutations in the OTOF (otoferlin) gene, into the clinic and further develop our pipeline of programs that leverage various AAV-mediated modalities to treat multiple inner ear disorders,” said Manny Simons, Ph.D., founder, president and CEO of Akouos. “We have built a team with deep experience and expertise, which will be a tremendous asset as we continue to execute on our mission to make healthy hearing available to all.”Recent Business Highlights * Appointed Alan Smith, Ph.D., as chief technology officer – In June 2020, Alan Smith, Ph.D., joined Akouos as chief technology officer. Dr. Smith brings over 30 years of experience in cellular therapeutics and previously served as executive vice president, technical operations at Bellicum Pharmaceuticals. * Strengthened board of directors with appointment of Saira Ramasastry – In June 2020, Saira Ramasastry joined the board of directors of Akouos. Ms. Ramasastry currently serves as managing partner of Life Sciences Advisory, a firm that she founded to provide strategic advice and business development solutions for life science companies. * Expanded the role of Arthur Tzianabos, Ph.D. to chairman of board of directors – In August 2020, Akouos announced the appointment of its board member Arthur Tzianabos to chairman of the board of directors. * Completed upsized Initial Public Offering – In June 2020, Akouos completed its initial public offering of 14,375,000 shares of common stock at a public offering price of $17.00 per share, including the full exercise of the underwriter’s option to purchase additional shares. Gross proceeds from the IPO were $244.4 million and net proceeds from the offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $223.8 million. * Presented two posters at the American Society of Gene & Cell Therapy 23rd Annual Meeting – In May 2020, Akouos presented two posters highlighting Akouos’s use of AAVAnc80 vector technology and its potential to address many forms of hearing loss.Second Quarter 2020 Financial Results * Cash Position – Cash and cash equivalents were $333.0 million as of June 30, 2020, as compared to $120.2 million as of March 31, 2020. Total cash, cash equivalents and marketable securities at June 30, 2020 includes total net proceeds of approximately $223.8 million from the company’s IPO in June 2020. Akouos expects the cash balance to fund operations for at least the next two years. * Research and Development (R&D) Expenses – R&D expenses were $9.9 million for the second quarter ended June 30, 2020, compared to $4.4 million for the same period in 2019. The increase was primarily due to contract manufacturing costs, the initiation of preclinical IND-enabling studies for AK-OTOF, and the growth in the number of R&D employees and their related activities, as well as the expense allocated to R&D related to Akouos’s leased facilities. * General and Administrative (G&A) Expenses – G&A expenses were $2.7 million for the second quarter ended June 30, 2020, compared to $0.7 million for the same period in 2019. The increase was primarily due to the growth in the number of G&A employees and other administrative expenses, as well as the expense allocated to G&A related to Akouos’s leased facilities. * Net Loss – Net loss was $12.5 million, or $11.14 loss per share, for the second quarter ended June 30, 2020, compared to $2.0 million, or $3.42 loss per share, for the same period in 2019.About AkouosAkouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation, and timing, of our future clinical trials and our research and development programs, and the period over which we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: our plans to develop and, if approved, subsequently commercialize our product candidates; the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for, our product candidates; our expectations regarding our regulatory strategy; our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash and cash equivalents; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential addressable patient population for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates; our intellectual property position; our ability to identify additional products, product candidates, or technologies with significant commercial potential that are consistent with our commercial objectives; the impact of government laws and regulations; our competitive position and expectations regarding developments and projections relating to our competitors and any competing therapies that are or become available; developments and expectations regarding developments and projections relating to our competitors and our industry; the impact of the COVID-19 pandemic on our business, results of operations, and financial condition; our ability to maintain and establish collaborations or obtain additional funding; and other factors discussed in the “Risk Factors” included in the Company’s final prospectus related to its initial public offering filed with the Securities and Exchange Commission, and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Condensed Consolidated Balance Sheet Data  (Unaudited)(in thousands)          June 30, 2020 December 31, 2019        Cash and cash equivalents $ 333,004 $ 25,078  Total assets   354,154   45,162  Total liabilities   21,898   19,273  Convertible preferred stock   —   58,690  Total stockholders’ equity (deficit)   332,256   (32,801) Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)(in thousands, except share and per share data)                Three Months Ended  Six Months Ended   June 30,  June 30,    2020  2019  2020  2019            Operating expenses:             Research and development $ 9,937  $ 4,366  $ 17,971  $ 7,509  General and administrative   2,664    749    5,168    1,380  Total operating expenses   12,601    5,115    23,139    8,889  Loss from operations   (12,601)   (5,115)   (23,139)   (8,889) Other income (expense):             Change in fair value of preferred stock tranche liability   —    3,013    —    753  Interest income   80    100    180    228  Other income (expense), net   (2)   (2)   (4)   (5) Total other income (expense), net   78    3,111    176    976  Net loss and comprehensive loss $ (12,523) $ (2,004) $ (22,963) $ (7,913) Net loss per share attributable to common stockholders, basic and diluted $ (11.14) $ (3.42) $ (25.05) $ (13.91) Weighted‑average common shares outstanding, basic and diluted   1,124,251    586,616    916,521    568,811  ContactsMedia:Katie Engleman, 1AB katie@1abmedia.comInvestors:Courtney Turiano, Stern Investor Relations Courtney.Turiano@sternir.com

    • GlobeNewswire

      Akouos Announces Expansion of Executive Team and Board of Directors

      Alan Smith, Ph.D., Joins as Chief Technology Officer Saira Ramasastry Joins Board of Directors; Arthur Tzianabos, Ph.D., Role Expanded to ChairmanBOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Alan Smith, Ph.D., as chief technology officer. In addition, the company announced that Saira Ramasastry has been appointed to its board of directors as audit committee chair, and board member Arthur Tzianabos, Ph.D., has been appointed chairman of the board.“Alan brings terrific experience in the development and manufacturing of complex biologics, and a proven track record of building teams and establishing infrastructure to support in-house GMP manufacturing capabilities,” said Manny Simons, Ph.D., founder, president, and chief executive officer of Akouos. “Alan joins Akouos at a pivotal time as we prepare to advance our lead program, AK-OTOF, to IND submission next year. We are also excited to welcome Saira, an esteemed life science leader, to our board of directors, and delighted to expand Arthur’s role to chairman of our board. Together, these appointments will be instrumental as Akouos continues to grow into a fully integrated genetic medicine company developing innovative potential therapies for a variety of inner ear disorders.”Dr. Smith joins Akouos with more than 30 years of experience in research and development, manufacturing, and quality in the areas of cell and gene therapies. He has contributed to more than 25 FDA regulatory submissions for cell therapy products and devices. Prior to Akouos, Dr. Smith was executive vice president, technical operations at Bellicum Pharmaceuticals, where he led cell product manufacturing, viral vector manufacturing, process development, assay development, GMP supply chain and logistics, worldwide facilities functions, and the design, construction, and startup of multiple GMP manufacturing facilities. Previously, Dr. Smith was vice president of research and development and cellular therapeutics for LifeNet Health and its subsidiary, The Institute of Regenerative Medicine. Earlier in his career, Dr. Smith served as president and chief executive officer for Cognate BioServices Inc. and chief operating officer and senior vice president of research and development for Osiris Therapeutics, Inc. Dr. Smith is also a former adjunct professor at Eastern Virginia Medical School, California State University, Long Beach and Utah State University. He holds a B.S. in chemistry from Southern Utah University and a Ph.D. in biochemistry from Utah State University.Ms. Ramasastry is managing partner of Life Sciences Advisory, a firm that she founded to provide strategic advice and business development solutions for life science companies. Ms. Ramasastry is also a health innovator fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. Prior to founding Life Sciences Advisory, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, and strategic and capital markets transactions. Prior to joining Merrill Lynch, she served as a financial analyst in mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry currently serves on the board of directors for Vir Biotechnology Inc., Glenmark Pharmaceuticals Ltd., and Sangamo Therapeutics, Inc. She holds a B.A. in economics with honors and distinction and an M.S. in management science and engineering from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge, where she is a guest lecturer for the Bioscience Enterprise Programme and previously served on the Cambridge Judge Business School Advisory Council.Initially appointed as an independent director to Akouos’s board of directors in July 2018, Dr. Tzianabos has now been appointed to serve as chairman. Dr. Tzianabos is currently the chief executive officer and president of Homology Medicines, Inc., leading the efforts to develop genetic medicines for patients with rare genetic diseases.  Previously, Dr. Tzianabos spent nine years at Shire Plc, where he worked on the development and launches of multiple treatments for patients with rare genetic disorders. Prior to joining Shire, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He serves on the board of directors for Stoke Therapeutics, Inc., the Alliance for Regenerative Medicine, and the development board for the University of New Hampshire’s College of Life Sciences and Agriculture. Dr. Tzianabos holds a B.S. in biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.About Akouos Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.Contact Media: Katie Engleman, 1AB katie@1abmedia.comInvestors: Courtney Turiano, Stern Investor Relations Courtney.Turiano@sternir.com